ANDREA RABE: Open Payments
NPI 1457639296 · KEARNEY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$226 in 13 payments from 8 companies in 2025. Trend: 2023 $230 · 2024 $508 · 2025 $226
Food & beverage: $226
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $62 |
| Lundbeck LLC | 2 | $35 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $33 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| PFIZER INC. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| GlaxoSmithKline, LLC. | 1 | $14 |
Products named: REXULTI, XIFAXAN, Ozempic, Rybelsus, CAPLYTA, MOUNJARO, PREVNAR 20, SHINGRIX.
Industry payments across NE — which companies pay providers there.
